Ultomiris (ravulizumab-cwvz)

About Xencor

Xencor is a publicly traded biotechnology company focused on redesigning antibody drugs from the ground up using its core XmAb Fc domain engineering platform. The company has established a robust pipeline of over 20 clinical-stage programs and has successfully partnered its technology, resulting in three marketed drugs. Xencor's strategy combines proprietary drug development in oncology and autoimmunity with a prolific licensing model that extends its technology to major pharmaceutical partners.

Therapeutic Areas